Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.
Post-traumatic stress disorder (PTSD), panic disorder, and panic attacks
Target patient population:
Patients over 13 years old with PTSD, panic disorder, or suffering from panic attacks associated with other medical or behavioral health conditions
What to expect:
Significant reduction or elimination of panic and/or PTSD symptoms
Indications for use:
Freespira is indicated as an adjunctive treatment for symptoms associated with panic disorder (PD) and/or post-traumatic stress disorder (PTSD), to be used under the direction of a healthcare professional, together with other pharmacological and/or non-pharmacological interventions
Panic: 86% panic attack free immediately post-treatment; 73% panic attack free 12 months post-treatment; 94% clinically significant reduction in panic symptoms at 12 months post-treatment; and 85% treatment adherence
PTSD: At 6-months post-treatment, 89% had significant reduction in symptoms based on CAPS-5 Score (validated PTSD assessment); 50% of patients were in remission; and 77% treatment adherence
After receiving training by a clinician or Freespira coach, patients complete an at-home 28-day protocol with two 17-minute breathing sessions each day, for one month. Four weekly virtual coaching sessions are also included.
Risks & warnings:
Not indicated for patients who are younger than 13 years old, are pregnant, or have chronic obstructive pulmonary disease (COPD) or emphysema
Place in therapy:
Freespira is adjunctive to current treatments for PTSD and panic. However, neither psychotherapy nor medications are required for patients using Freespira.
Freespira is a digital therapeutic product that incorporates a handheld tablet with pre-loaded software that provides patients with specific breathing protocols, in addition to a device that measures patient breathing rate and exhaled carbon dioxide in real time. Respiratory information is uploaded to a secure server for review by the Freespira coach and/or patient’s therapist. The patient receives virtual personalized training and coaching.
Authorization from a licensed healthcare provider is required. A prescription from a physician is not necessary.
Patients may self-refer into the program or are referred by a healthcare provider. The Freespira Patient Care Team determines any necessary copay/coinsurance payments, collects payments or creates a flexible payment plan, then ships devices to the patient’s home and schedules training. The Freespira device is self-contained and does not require additional equipment.
Healthcare providers are able to access the Freespira dashboard using a unique login and password to monitor patient progress as they work toward meeting their daily/weekly goals during the 28-day protocol. This dashboard also provides clinical outcomes, using data from the symptom assessments that patients complete each week.
Coverage examples include Highmark Health and Children’s Community Health Plan, who offer Freespira as a covered benefit for eligible insurance members with panic disorder, panic attacks, or PTSD. For patients who receive Freespira through employers, Comcast for example, there are no out-of-pocket costs associated with product use. Freespira is also offered as a self-pay product if insurance companies do not offer coverage.
Freespira is available in:
The only FDA-cleared, evidence-based, drug-free digital therapeutic that can reduce or eliminate the symptoms of panic disorder, panic attacks, and PTSD